天美传媒

Dr. Inderpal Randhawa is a leading specialist with board certifications in allergy, immunology, pulmonology, general pediatrics, and internal medicine. He gained interest in food allergy while serving as a sub-investigator in an early study utilizing Omalizumab (Trade name: Xolair). Meanwhile, he was witnessing a dramatic and unprecedented increase in the number of pediatric patients admitted to the intensive care unit as the result of anaphylaxis. The severity and frequency of these cases drove Dr. Randhawa to question the direction of food allergy treatment and motivated him to find more effective solutions than those from clinical trials.

In addition, Dr. Randhawa had experience desensitizing lung transplant patients with life-threatening allergies to critical and indispensable anti-rejection drugs that utilized a patient-specific desensitization protocol. These experiences, and his collaboration with national allergy and immunology specialists, informed Dr. Randhawa鈥檚 precision medicine approach to treating food allergy. Since 2005, he has successfully treated more than 2,000 patients with life-threatening allergies to peanut, tree nuts, milk, egg, wheat, soy, seafood, seeds, and other foods using his unique, research-based Tolerance Induction Program, achieving an unmatched 99% rate of success.

Dr. Randhawa serves as the program director and research coordinator in two fellowship programs at the David Geffen UCLA School of Medicine and UC Irvine 鈥� Miller Children鈥檚 Hospital. In addition, he practices clinical medicine in pulmonary diseases, immune deficiencies, allergy and transplant medicine. Dr. Randhawa is also the Founder and Medical Director of the Translational Pulmonary and Immunology Research Center (TPIRC).

Dr. Randhawa received his medical degree from Northwestern University鈥檚 Feinberg School of Medicine. After completing a combined internal medicine/pediatrics residency, he completed training in Clinical Immunology & Allergy at UCLA and pediatric and adult pulmonology at UC Irvine 鈥� Miller Children鈥檚 Hospital. Dr. Randhawa has authored over 150 peer reviewed abstracts and research publications and has served as primary investigator in over 25 clinical trials.

Susan R. Bailey, MD, an allergist/immunologist from Fort Worth, Texas, was elected president of the American Medical Association in June 2020. Previously, she served as president-elect of the AMA for one year, speaker of the AMA House of Delegates for four years and as vice speaker for four years.

Dr. Bailey, who has been active in the AMA since medical school when she served as chair of the AMA Medical Student Section, has held numerous leadership positions with the AMA. These include serving as chair of both the Advisory Panel on Women in Medicine and the AMA Council on Medical Education, as well as representing the AMA on the Accreditation Council for Continuing Medical Education, the American Board of Medical Specialties, and COLA.

Her long history of service in helping guide organized medicine extends to the local and state levels as well. She has served as board chair and president of the Tarrant County Medical Society, and as vice speaker, speaker and president of the Texas Medical Association.

Dr. Bailey is an allergist in private practice, and has been with Fort Worth Allergy and Asthma Associates for over 30 years. She completed her residency in general pediatrics and a fellowship in allergy/immunology at the Mayo Graduate School of Medicine in Rochester, Minn., and is board certified in allergy and immunology, and pediatrics and has been awarded the title of Distinguished Fellow of the American College of Allergy, Asthma, and Immunology.

In addition to receiving her medical degree with honors from the Texas A&M University College of Medicine
as a member of its charter class, Dr. Bailey was later appointed to the Texas A&M System Board of Regents by then Gov. George W. Bush, and has been named a Distinguished Alumnus of Texas A&M University and of Texas A&M University College of Medicine.